Originally posted by BigDaniel
Thanks Bull.
I can completely understand investors like yourself wanting answers to these questions, they are often important bench marks & performance indicators.
CGL is a complicated investment due to the infancy of it's targeted industries.
CGL has always been a high risk investment & remains so to this day. Last weeks BioHealth binding-MOU announcment has significantly de-risked the company however there is still hard work to be done.
I believe forecasting revenue figures at this early stage would be a mistake, particurly after a difficult first harvest last year.
I'd like to see the company finalize the re-compliance process & re-list before anything
Upon re-lisitng we then need to see CGL focus their energy on the manufacturing of initial inventory to coincide with a well executed plan into the Australian/Asian markets.
Hopefully at the same time we see some favourable news regarding harvests.
I'd be okay with the company testing the overseas markets & perfecting a harvest before releasing any forecast figures.
Better to pleasantly suprise the market than over promise.
Perhaps 2020 will be the year to set firmer targets?
Perhaps CGL management are planning to release figures shortly? No idea really,
Not everyone is going to share my analysis of CGL but I'm really just trying to take the common sense approach to a highly speculative stock & apply logic when I can.
I welcome yours & any other investors opinions Bull regarding this.
Dan.
I appreciate that everyone has different opinions but i still struggle to see how this is a positive and has derisked things? If CGB had acquired medcan, they would own their own full suite of licences and wouldn't need to pay other companies to grow and manufacture for them.. i believe it has made it far more risky. If they owned the licences themselves they could always fall back on those alone for a use in the industry. What happens if biohealth pull out of the deal? Where would that leave CGB? I also just had a thought.. bio health dont have an ODC medicinal cannabis manufacture licence. They are licenced to make capsules, powders etc etc products.. but no mention of cannabis licences, which they obviously require. Or have i missed something? On top of that, i still dont see where they're going to set their plant material from. Even if it is medcan (i doubt it will be... not for cheap anyway), arent you guys saying they're still years off having the facilties up and running?
